Morgan Stanley raised its price target for Hinge Health (NYSE:HNGE) to $108 from $72. This adjustment represents a 50% increase while the bank maintains an Overweight rating.
Analysts increased revenue and earnings estimates for the 2026 through 2028 period. The bank cited better-than-expected yield as a primary driver for the revised forecast.
The decision also reflects an expanded valuation multiple. Morgan Stanley aligned this multiple with growth trends seen in comparable software stocks. The move signals strong confidence in the company's long-term execution and growth trajectory.